Skip to main content

Together we are beating cancer

Donate now
  • Science & Technology

First womb cancer genome scan reveals prostate cancer link

The Cancer Research UK logo
by Cancer Research UK | News

18 April 2011

0 comments 0 comments

Scientists have carried out the first ever genome scan for womb cancer and discovered a genetic region that reduces risk of the disease, according to a study published in Nature Genetics today (Sunday).

In men a gene within the same region – called HNF1B – has previously been linked to lower prostate cancer risk, but higher risk of type-2 diabetes.

The study – funded by Cancer Research UK, the National Health and Medical Research Council in Australia and the Wellcome Trust** – is the first to find a genetic link between these two different cancer types.

Women with the protective ‘version’ of the gene are on average 15-18 per cent less likely to develop womb cancer, while men with the same version are 21 per cent less likely to develop prostate cancer. It has also been linked to a 10-14 per cent greater risk of developing type-2 diabetes.

Lead author Professor Douglas Easton, director of Cancer Research UK’s Genetic Epidemiology Unit at the University of Cambridge, said: “This study is the first to highlight a potential link between womb cancer in women and prostate cancer in men, providing new insight into the underlying genes and mechanisms that lead to the development of both diseases.

“Understanding how these influence a person’s risk of developing cancer is a crucial step in being able to identify high risk groups who may benefit from closer monitoring or measures to reduce their risk of developing the disease.”

In the hunt for genes linked to womb cancer, the researchers began by scanning the genomes of 1,265 womb cancer patents and comparing them to the genomes of 5,190 women who didn’t have the disease.

This allowed them to pinpoint a total of 47 different one-letter alterations in the genetic code – known as single nucleotide polymorphisms (SNPs) – where genes linked to womb cancer were most likely to be found.

They then narrowed down their search by looking specifically at these regions in a further 3,957 patients with womb cancer and 6,886 without the disease.

This left just three SNPs that were shown to be significantly linked to a decreased risk of womb cancer, all of which overlapped with the gene HNF1B on chromosome 17.

Dr Lesley Walker, director of cancer information at Cancer Research UK, said: “This is only the second common genetic region to have been linked to the development of womb cancer.

“With faster, cheaper genome technologies now becoming available, we are on the cusp of being able to carry out powerful genome studies involving much larger groups of people. This will allow scientists to pinpoint subtler associations helping to build a more complete picture of how genes influence a person’s risk of developing womb cancer. Ultimately this will pave the way for more targeted approaches to treating and diagnosing the disease.”


For media enquiries please contact the Cancer Research UK press office on 020 3469 8300 or, out-of-hours, the duty press officer on 07050 264 059.